secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078622
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025
--------------------------------------------------------------------------------

- First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.
- Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.
- Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.
- Cash and cash equivalents of $8.9M as of June 30, 2025.
- FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/0001104659-25-078622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer